Literature DB >> 12352673

Round window gentamicin absorption: an in vivo human model.

Zoran Becvarovski1, Dennis I Bojrab, Elias M Michaelides, Jack M Kartush, John J Zappia, Michael J LaRouere.   

Abstract

OBJECTIVE/HYPOTHESIS: Using a novel human labyrinthine sampling model, in vivo gentamicin absorption through the round window can be measured. STUDY
DESIGN: A prospective study.
METHODS: Gentamicin was delivered either transtympanically (preoperative) or through a facial recess approach (intraoperative). The lateral semicircular canal and vestibule were opened, and by means of a microsyringe, labyrinthine fluid was aspirated. A sample of serum was also drawn. In all patients cerebrospinal fluid was also drawn. The samples were analyzed using a standard chemistry analyzer.
RESULTS: Intratympanic gentamicin diffused through the round window membrane and achieved concentrations in the labyrinthine fluid ranging from 0 to 16 mg/L. Intratympanic gentamicin was absorbed into the systemic circulation in 4 of 11 patients with serum levels ranging from 0.3 to 0.4 mg/L. No gentamicin was detected in the cerebrospinal fluid.
CONCLUSIONS: Intratympanic gentamicin diffuses rapidly through the round window membrane and achieves significant levels in the inner ear. Thus, this new model can be used to assess round window permeability to clinically relevant medications such as steroids and ototopical antibiotics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352673     DOI: 10.1097/00005537-200209000-00015

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  12 in total

1.  Inner ear insult ablates the arousal response to hypoxia and hypercarbia.

Authors:  T Allen; A J Garcia Iii; J Tang; J M Ramirez; D D Rubens
Journal:  Neuroscience       Date:  2013-09-08       Impact factor: 3.590

Review 2.  Local inner-ear drug delivery and pharmacokinetics.

Authors:  Alec N Salt; Stefan K R Plontke
Journal:  Drug Discov Today       Date:  2005-10-01       Impact factor: 7.851

3.  Pharmacokinetics of Drug Entry into Cochlear Fluids.

Authors:  Alec N Salt
Journal:  Volta Rev       Date:  2005

4.  Endoscopic tympanoplasty type I for tympanic perforations: analysis of prognostic factors.

Authors:  Matteo Fermi; Francesco Maccarrone; Domenico Villari; Filippo Palermo; Matteo Alicandri-Ciufelli; Michael Ghirelli; Livio Presutti; Marco Bonali
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-12       Impact factor: 2.503

5.  Ototoxic destruction by co-administration of kanamycin and ethacrynic acid in rats.

Authors:  Hong Liu; Da-lian Ding; Hai-yan Jiang; Xue-wen Wu; Richard Salvi; Hong Sun
Journal:  J Zhejiang Univ Sci B       Date:  2011-10       Impact factor: 3.066

6.  Gentamicin Applied to the Oval Window Suppresses Vestibular Function in Guinea Pigs.

Authors:  E B King; R K Shepherd; D J Brown; J B Fallon
Journal:  J Assoc Res Otolaryngol       Date:  2017-01-03

7.  Marker entry into vestibular perilymph via the stapes following applications to the round window niche of guinea pigs.

Authors:  Alec N Salt; Elisha B King; Jared J Hartsock; Ruth M Gill; Stephen J O'Leary
Journal:  Hear Res       Date:  2011-12-08       Impact factor: 3.208

8.  Temporal and spatial distribution of gentamicin in the peripheral vestibular system after transtympanic administration in guinea pigs.

Authors:  Ru Zhang; Yi-Bo Zhang; Chun-Fu Dai; Peter S Steyger
Journal:  Hear Res       Date:  2013-02-01       Impact factor: 3.208

9.  Cochlear changes in serous labyrinthitis associated with silent otitis media: A human temporal bone study.

Authors:  Serdar Kaya; Vladimir Tsuprun; Ömer Hızlı; Patricia A Schachern; Michael M Paparella; Sebahattin Cureoglu
Journal:  Am J Otolaryngol       Date:  2015-10-08       Impact factor: 1.808

10.  Permeation Enhancers for Intratympanically-applied Drugs Studied Using Fluorescent Dexamethasone as a Marker.

Authors:  Wei Li; Jared J Hartsock; Chunfu Dai; Alec N Salt
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.